{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:13:02Z","timestamp":1789182782470,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"crossref","award":["ET-D-022-11"],"award-info":[{"award-number":["ET-D-022-11"]}],"id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00432-018-2637-1","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T20:30:17Z","timestamp":1523046617000},"page":"1185-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study"],"prefix":"10.1007","volume":"144","author":[{"given":"Ingo B.","family":"Runnebaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Ringsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"2637_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415\u2013428. \n                    https:\/\/doi.org\/10.1038\/nrc2644","journal-title":"Nat Rev Cancer"},{"key":"2637_CR2","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2010.29.7077","volume":"28","author":"SA Cannistra","year":"2010","unstructured":"Cannistra SA (2010) Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 28:3101\u20133103. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.29.7077","journal-title":"J Clin Oncol"},{"key":"2637_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","volume":"60","author":"N Colombo","year":"2006","unstructured":"Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I (2006) Ovarian cancer. Crit Rev Oncol hematol 60:159\u2013179. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2006.03.004","journal-title":"Crit Rev Oncol hematol"},{"key":"2637_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","volume":"17","author":"G Corrado","year":"2017","unstructured":"Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G (2017) Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther 17:1147\u20131158. \n                    https:\/\/doi.org\/10.1080\/14737140.2017.1398088","journal-title":"Expert Rev Anticancer Ther"},{"key":"2637_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fon.13.207","volume":"9","author":"M D\u2019Incalci","year":"2013","unstructured":"D\u2019Incalci M (2013) Trabectedin mechanism of action: what\u2019s new? Future Oncol 9:5\u201310. \n                    https:\/\/doi.org\/10.2217\/fon.13.207","journal-title":"Future Oncol"},{"key":"2637_CR6","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","volume":"9","author":"M D\u2019Incalci","year":"2010","unstructured":"D\u2019Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9:2157\u20132163. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0263","journal-title":"Mol Cancer Ther"},{"key":"2637_CR7","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD et al (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188\u20134196. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.21.0088","journal-title":"J Clin Oncol"},{"key":"2637_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2637_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/IGC.0000000000001058","volume":"27","author":"G Ferrandina","year":"2017","unstructured":"Ferrandina G et al (2017) Real-world management of trabectedin\/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: a national survey. Int J Gynecol Cancer 27:1141\u20131148. \n                    https:\/\/doi.org\/10.1097\/IGC.0000000000001058","journal-title":"Int J Gynecol Cancer"},{"key":"2637_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M et al (2011) Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 21:771\u2013775. \n                    https:\/\/doi.org\/10.1097\/IGC.0b013e31821bb8aa","journal-title":"Int J Gynecol Cancer"},{"key":"2637_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1586\/era.09.165","volume":"10","author":"P Harter","year":"2010","unstructured":"Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A (2010) Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 10:81\u201388. \n                    https:\/\/doi.org\/10.1586\/era.09.165","journal-title":"Expert Rev Anticancer Ther"},{"key":"2637_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","volume":"77","author":"AK Larsen","year":"2016","unstructured":"Larsen AK, Galmarini CM, D\u2019Incalci M (2016) Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol 77:663\u2013671. \n                    https:\/\/doi.org\/10.1007\/s00280-015-2918-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"2637_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10637-011-9662-0","volume":"30","author":"A Cesne Le","year":"2012","unstructured":"Le Cesne A et al (2012) A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Investig New Drugs 30:1193\u20131202. \n                    https:\/\/doi.org\/10.1007\/s10637-011-9662-0","journal-title":"Investig New Drugs"},{"key":"2637_CR14","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ et al (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107\u20133114. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.25.4037","journal-title":"J Clin Oncol"},{"key":"2637_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000441378","volume":"61","author":"G Moriceau","year":"2016","unstructured":"Moriceau G et al (2016) Real-world outcomes of combination chemotherapy with trabectedin plus pegylated liposomal doxorubicin in patients with recurrent ovarian cancer: a single-center experience. Chemotherapy 61:122\u2013126. \n                    https:\/\/doi.org\/10.1159\/000441378","journal-title":"Chemotherapy"},{"key":"2637_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5301\/tj.5000371","volume":"101","author":"MO Nicoletto","year":"2015","unstructured":"Nicoletto MO et al (2015) Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer. Tumori 101:506\u2013510. \n                    https:\/\/doi.org\/10.5301\/tj.5000371","journal-title":"Tumori"},{"key":"2637_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ctrv.2013.08.001","volume":"40","author":"A Poveda","year":"2014","unstructured":"Poveda A, Ray-Coquard I, Romero I, Lopez-Guerrero JA, Colombo N (2014) Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat Rev 40:366\u2013375. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2013.08.001","journal-title":"Cancer Treat Rev"},{"key":"2637_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","unstructured":"The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609\u2013615. \n                    https:\/\/doi.org\/10.1038\/nature10166","journal-title":"Nature"},{"key":"2637_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2637_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108. \n                    https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"key":"2637_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719\u2013725. \n                    https:\/\/doi.org\/10.1038\/nrc3144","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2637-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T07:26:29Z","timestamp":1589873189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2637-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2637-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"21 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ingo Runnebaum has received funding for this study and a speaker honorarium from PharmaMar and was a member of advisory board of PharmaMar. Jalid Sehouli is a member of advisory board of Roche, Clovis, Tesaro and Astra Zeneca, and has received founding from PharmaMar and Medac. Pauline Wimberger has received a speaker honorarium from PharmaMar for scientific talks. All other authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, guidelines for Good Pharmacoepidemiology Practice and the German Drug Law (AMG, \u00a7\u00a067[6]), and were approved by the institutional review boards of each participating center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}